ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting • Phase II • NCT06470048.
- Trial tested whether ianalumab injections could safely improve diffuse cutaneous systemic sclerosis compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo Conditions: Diffuse Cutaneous Systemic Sclerosis Interventions: Placebo, Ianalumab Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 200 participants